+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases



Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases



Cancer 89(6): 1228-1235



BACKGROUND: Pharmacokinetic modulating chemotherapy (PMC) is a new therapeutic concept in combination with continuous 5-fluorouracil (5-FU) infusion and UFT. UFT enhanced plasma 5-FU concentration and antitumor effects during 5-FU infusion. The authors report on their experiences with arterial 5-FU infusion and UFT after resection of hepatic colorectal secondaries. METHODS: Fifty-eight patients were divided into two groups after hepatectomy. Group A, 30 patients, underwent hepatic arterial infusion (HAI) via implantable port system with perfusion 5-FU for 2 consecutive days per week at 600 mg/m2/day, and oral administration of UFT at 400 mg/day for 5-7 days per week, repeated 10 times, and Group B, 28 patients, underwent oral administration of UFT at 400 mg/day for 6 months. All the patients were managed at the outpatient clinic at Hyogo College of Medicine, and recurrence, survival, and toxicity were documented. Plasma 5-FU concentrations during chemotherapy were detected using high performance liquid chromatography. RESULTS: Maximum plasma concentrations of 5-FU in Group A reached 144.0 ng/mL and in Group B 58.7 ng/mL. Cumulative 5-year survival rate after hepatectomy in Group A was 59% and in Group B was 27%. (P = 0.00001) HAI-PMC drastically decreased hepatic recurrence (median hepatic recurrence free times were 34.2 months in Group A vs. 18.4 months in Group B; P = 0.00002). Grade 3 toxicity in Group A was found in 3 patients CONCLUSIONS: Pharmacokinetic modulating chemotherapy was designed as a uracil-related biochemical modulation. HAI-PMC significantly decreased hepatic recurrence after curative resection. This new chemotherapy concept significantly improved prognosis in patients with hepatic colorectal metastases.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011295743

Download citation: RISBibTeXText

PMID: 11002217

DOI: 10.1002/1097-0142(20000915)89:6<1228::aid-cncr6>3.0.co;2-o


Related references

Clinical results of pharmacokinetic modulating chemotherapy (PMC) in combination with hepatic arterial 5FU infusion, continuous venous 5FU infusion and oral UFT as adjuvant chemotherapy after liver resection for hepatic colorectal metastases. Journal of Clinical Oncology 23(16_Suppl): 3665-3665, 2016

Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Annals of Oncology 12(5): 599-603, 2001

Hepatic arterial infusion with oxaliplatin, folinic acid, and 5-fluorouracil in patients with hepatic metastases from colorectal cancer Results of a phase I and pharmacokinetic study. Onkologie 23(Sonderheft 7): 14, 2000

Phase I trial of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (DEX) in combination with systemic oxaliplatin (OXAL), fluorouracil (FU) + leucovorin (LV) after resection of hepatic metastases from colorectal cancer. Journal of Clinical Oncology 23(16_Suppl): 3579-3579, 2016

Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin, folinic acid, and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Anticancer Research 19(6D): 5683-5684, 1999

Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with unresectable liver metastases from colorectal cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(13): 2033-2037, 2007

A pilot study of adjuvant hepatic arterial infusion chemotherapy, associating 5-fluorouracil and leucovorin, after resection of colorectal cancer liver metastases. Surgical Oncology 4(6): 317-322, 1995

The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 31(11): 1743-1745, 2004

Results of prophylactic intra-arterial infusion chemotherapy after hepatic resection in colorectal metastases. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 17(8 Pt 2): 1824-1827, 1990

Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. Gastroenterologie Clinique et Biologique 24(6-7): 690-691, 2000

Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. New England Journal of Medicine 341(27): 2039-2048, 1999

Evaluation of hepatic resection following hepatic arterial infusion chemotherapy for colorectal liver metastases. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(12): 1826-1829, 2000

Hepatic arterial chemotherapy in combination with systemic chemotherapy compared with hepatic arterial chemotherapy alone for liver metastases from colorectal cancer: Results of a multi-centric randomized study. In Vivo (Attiki) 20(6A): 707-709, 2006

Hepatic arterial chemotherapy in combination with systemic chemotherapy compared with hepatic arterial chemotherapy alone for liver metastases from colorectal cancer: results of a multi-centric randomized study. In Vivo 20(6a): 707-709, 2007

Evaluation of prophylactic intra-hepatic-arterial infusion chemotherapy after resection of hepatic metastases from colorectal primaries. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(13): 2158-2161, 1994